Radiation Oncology Journal

  • 제33권1호
  • /
  • Pages.21-28
  • /
  • 2015
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer

  • Schreiber, David (Department of Veterans Affairs, New York Harbor Healthcare System) ;
  • Rineer, Justin (University of Florida Health Cancer Center at Orlando Health) ;
  • Weiss, Jeffrey P. (Department of Veterans Affairs, New York Harbor Healthcare System) ;
  • Safdieh, Joseph (Department of Veterans Affairs, New York Harbor Healthcare System) ;
  • Weiner, Joseph (Department of Veterans Affairs, New York Harbor Healthcare System) ;
  • Rotman, Marvin (Department of Veterans Affairs, New York Harbor Healthcare System) ;
  • Schwartz, David (Department of Veterans Affairs, New York Harbor Healthcare System)
  • 투고 : 2014.12.02
  • 심사 : 2015.01.22
  • 발행 : 2015.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: We analyzed outcomes of patients with prostate cancer undergoing either radical retropubic prostatectomy (RRP) +/- salvage radiation or definitive radiation therapy (RT) +/- androgen deprivation. Materials and Methods: From 2003-2010 there were 251 patients who underwent RRP and 469 patients who received RT (${\geq}7,560cGy$) for prostate cancer. Kaplan-Meier analysis was performed with the log-rank test to compare biochemical control (bCR), distant metastatic-free survival (DMPFS), and prostate cancer-specific survival (PCSS) between the two groups. Results: The median follow-up was 70 months and 61.3% of the men were African American. For low risk disease the 6-year bCR were 90.3% for RT and 85.6% for RRP (p = 0.23) and the 6-year post-salvage bCR were 90.3% vs. 90.9%, respectively (p = 0.84). For intermediate risk disease the 6-year bCR were 82.6% for RT and 59.7% for RRP (p < 0.001) and 82.6% vs. 74.0%, respectively, after including those salvaged with RT (p = 0.06). For high risk disease, the 6-year bCR were 67.4% for RT and 41.3% for RRP (p < 0.001) and after including those salvaged with RT was 67.4% vs. 43.1%, respectively (p < 0.001). However, there were no significant differences between the two groups in regards to DMPFS or PCSS. Conclusion: Treatment approaches utilizing RRP +/- salvage radiation or RT +/- androgen deprivation yielded equivalent DMPFS and PCSS outcomes. Biochemical control rates, using their respective definitions, appeared equivalent or better in those who received treatment with RT.

키워드

참고문헌

  1. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74. https://doi.org/10.1001/jama.280.11.969
  2. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25-33. https://doi.org/10.1016/S0360-3016(03)00784-3
  3. Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 2004;71:29-33. https://doi.org/10.1016/j.radonc.2003.12.011
  4. Klein EA, Ciezki J, Kupelian PA, Mahadevan A. Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? Urol Oncol 2009;27:67-71. https://doi.org/10.1016/j.urolonc.2008.04.001
  5. Aizer AA, Yu JB, Colberg JW, McKeon AM, Decker RH, Peschel RE. Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol 2009;93:185-91. https://doi.org/10.1016/j.radonc.2009.09.001
  6. Vassil AD, Murphy ES, Reddy CA, et al. Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology 2010;76:1251-7. https://doi.org/10.1016/j.urology.2010.01.010
  7. Rayala HJ, Richie JP. Radical prostatectomy reigns supreme. Oncology (Williston Park) 2009;23:863-7.
  8. Shah C, Jones PM, Wallace M, et al. Differences in disease presentation, treatment outcomes, and toxicities in African American patients treated with radiation therapy for prostate cancer. Am J Clin Oncol 2012;35:566-71. https://doi.org/10.1097/COC.0b013e3182208262
  9. Du KL, Bae K, Movsas B, Yan Y, Bryan C, Bruner DW. Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials. Support Care Cancer 2012;20:1317-25. https://doi.org/10.1007/s00520-011-1219-4
  10. Sundi D, Ross AE, Humphreys EB, et al. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol 2013;31: 2991-7. https://doi.org/10.1200/JCO.2012.47.0302
  11. Surapaneni A, Schwartz D, Nwokedi E, Rineer J, Rotman M, Schreiber D. Radiation therapy for clinically localized prostate cancer: long-term results of 469 patients from a single institution in the era of dose escalation. J Cancer Res Ther 2014;10:951-6. https://doi.org/10.4103/0973-1482.138096
  12. Safdieh JJ, Schwartz D, Weiner J, et al. Long-term tolerance and outcomes for dose escalation in early salvage post-prostatectomy radiation therapy. Radiat Oncol J 2014;32:179-86. https://doi.org/10.3857/roj.2014.32.3.179
  13. National Comprehensive Cancer Network guidelines on prostate cancer [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2015 [cited 2015 Feb 1]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
  14. Nielsen ME, Han M, Mangold L, et al. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol 2006;176:515-9. https://doi.org/10.1016/j.juro.2006.03.100
  15. Cross CK, Shultz D, Malkowicz SB, et al. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol 2002;20:2863-8. https://doi.org/10.1200/JCO.2002.11.054
  16. Tewari A, Horninger W, Badani KK, et al. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int 2005;96:29-33.
  17. Chu DI, Moreira DM, Gerber L, et al. Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 2012;118:4999-5007. https://doi.org/10.1002/cncr.27456
  18. Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 2011;71: 985-97. https://doi.org/10.1002/pros.21314
  19. Du XL, Fang S, Coker AL, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer 2006;106:1276-85. https://doi.org/10.1002/cncr.21732
  20. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540-5. https://doi.org/10.1016/j.juro.2006.10.097
  21. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-74. https://doi.org/10.1016/j.ijrobp.2006.04.029

피인용 문헌

  1. Comparison of biochemical recurrence in prostate cancer patients treated with radical prostatectomy or radiotherapy vol.56, pp.10, 2015, https://doi.org/10.4111/kju.2015.56.10.703
  2. The Treatments for Low-Risk Prostate Cancer vol.17, pp.1, 2015, https://doi.org/10.22465/kjuo.2019.17.1.7